Drugs / IxCell hUC-MSC-P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06823063 | Apr 2025 → Oct 2026 expected | interstitial lung disease | Shanghai IxCell Biotechnology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IxCell hUC-MSC-P | “A Phase I Clinical Trial to Evaluate the Safety and Tolerability of a Single Dose of Human Umbilical Cord Mesenchymal Stem Cell Injection (IxCell hUC-MSC-P) in Patients With...” NCT06823063 ↗ |
| Known as | Human Umbilical Cord Mesenchymal Stem Cells | “Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD” NCT06823063 ↗ |
| Modality | Cell therapy | “Human Umbilical Cord Mesenchymal Stem Cell Injection” NCT06823063 ↗ |
| Route | Intravenous | “a single injection dose i.v.” NCT06823063 ↗ |